Researcher/Special Engineer, Investigating Epi-transcriptomic Mechanisms in Cancer Progression

A position is available as Researcher or Special Engineer in the group of Adam Filipczyk in the Department of Microbiology, Section for Research, for the period 01.august 2024 - 30.september 2027.

We are interested in the role of RNA modifications in cancer molecular mechanisms and in a patient relevant setting. Recent pioneering work has shown the significance of epi-transcriptomic regulation in cancer progression and the field is expanding rapidly.

We are looking for enthusiastic and determined individuals who can work both independently as well as in a group environment. This research post will focus on characterizing novel mechanisms of gene regulation and identify the prognostic power of RNA modification deregulation in cancer progression.

Do you think this sounds exciting? Would YOU like to become our new colleague on our great team? Send us your application and we are looking forward to get to know YOU!

Oslo University Hospital is a workplace with great diversity. We believe this is absolutely crucial to solving the tasks required of us. We therefore want this diversity to be reflected among the applicants for our positions and encourage everyone to apply regardless of who you are and what background you have.

Qualifications:

The successful candidate:

• Is capable of conceptual thinking and is looking forward to learning new techniques.
• Has good communication skills and is well organized.

Knowledge and prior documented application of at least one of the following is a requirement:

1. High-throughput sequencing (Single cell RNA-seq, DRIP-Seq, ChIP-Seq, RIP-seq) and molecular/biochemical characterization in cancer and/or -
2. Application of patient derived cancer models (organoid/ xenograft).

Potential candidates have completed (or are close to completing) a PhD degree in molecular biology or medicine, with at least one publication in a high-impact, peer-reviewed scientific journal as the second requirement. Applicants with evidence of publications in press will also be considered.

1. A concise application letter explaining your motivation for this position (1-2 pages).
2. Curriculum vitae including a list of peer-reviewed publications.
3. Contact information of three references.

We can offer

The position will commence in the Summer of 2024 and will extend over a minimum of 3 years upon a successful evaluation period. A selection committee will contact chosen candidates two weeks after the closing deadline for interviews. Oslo University Hospital is an equal opportunity employer.

Relevant References:
N6-Methyladenosine (m6A) Depletion Regulates Pluripotency Exit by Activating Signaling Pathways in Embryonic Stem Cells. Jin K, Zuo H, Klungland A, Anastassiadis K, Marr C & Filipczyk A. Proc. Natl. Acad. Sci. U S A (PNAS), 118 (51), December, 2021.
Su Z, Monshaugen I, Wilson B, Wang F, Klungland A, Ougland R, Dutta A. TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer. Nature Communications. 2022 Apr 20;13(1):2165.
Reversible RNA modifications in meiosis and pluripotency. Klungland A, Dahl JA, Greggains G, Fedorcsak P, Filipczyk A. Nat Methods. 2017 Jan 29;14(1):18-22.